

APPENDIX A: PENDING CLAIMS

130. A non-invasive method for facilitating the diagnosis of a subject for a matrix metalloproteinase -associated (MMP-associated)) cancer, comprising:

obtaining a urine sample from a subject;

detecting the presence or absence of a matrix metalloproteinase in the urine sample; and

correlating the presence or absence of the matrix metalloproteinase with the presence or absence of the MMP-associated cancer, thereby facilitating the diagnosis of the subject for the MMP-associated cancer.

131. A non-invasive method using at least one biological marker to monitor the prognosis or diagnosis of a subject for a matrix metalloproteinase -associated (MMP-associated) cancer, comprising:

obtaining a urine sample from a subject; and

monitoring the prognosis or diagnosis of the subject for an MMP-associated cancer using at least one biological marker including a matrix metalloproteinase selected for its association with the cancer.

132. The method of claim 130 or 131, wherein the MMP-associated cancer is organ-confined prostate cancer.

133. The method of claim 130 or 131, wherein the MMP-associated cancer is metastatic prostate cancer.

U.S. Serial No. 09/469,637

- 15 -

Group Art Unit: 1623

134. The method of claim 130 or 131, wherein the MMP-associated cancer is in cells of epithelial origin.

135. The method of claim 130 or 131, wherein the MMP-associated cancer appears in cells of mesodermal origin.

136. The method of claim 130 or 131, wherein the MMP-associated cancer appears in cells of endodermal origin.

137. The method of claim 130 or 131, wherein the MMP-associated cancer affects cells of bone or of hematopoietic origin.

138. The method of claim 130 or 131, wherein the MMP-associated cancer is a cancer of the nervous system.

139. The method of claim 130 or 131, wherein the MMP-associated cancer is a breast cancer.

140. The method of claim 130 or 131, wherein the MMP-associated cancer is a retina cancer.

141. The method of claim 130 or 131, wherein the MMP-associated cancer is a lung cancer.

142. The method of claim 130 or 131, wherein the MMP-associated cancer is a skin cancer.

U.S. Serial No. 09/469,557

- 16 -

Group Art Unit: 1623

143. The method of claim 130 or 131, wherein the MMP-associated cancer is a kidney cancer.

144. The method of claim 130 or 131, wherein the MMP-associated cancer is a liver cancer.

145. The method of claim 130 or 131, wherein the MMP-associated cancer is a pancreatic cancer.

146. The method of claim 130 or 131, wherein the MMP-associated cancer is a cancer of the genito-urinary or gastrointestinal tract.

147. The method of claim 130 or 131, wherein the MMP-associated cancer is bladder cancer.

148. The method of claim 130 or 131, wherein the MMP-associated cancer is a lymphoma.

149. The method of claim 130 or 131, wherein the matrix metalloproteinase is a proenzyme.

150. The method of claim 130 or 131, further comprising removal of low molecular weight contaminants from the urine prior to the detection step.

151. The method of claim 130 or 131, wherein the urine is dialyzed.

U.S. Serial No. 09/469,637

- 17 -

Group Art Unit: 1623

152. The method of claim 130 or 131, wherein the subject has previously been treated surgically or hormonally.

153. The method of claim 130 or 131, wherein the subject has been treated to block testosterone.

154. The method of claim 130 or 131, wherein the matrix metalloproteinase is a gelatinase.

155. The method of claim 130 or 131, wherein the matrix metalloproteinase has a molecular weight of approximately 72 kDa.

156. The method of claim 130 or 131, wherein the matrix metalloproteinase has a molecular weight of approximately 92 kDa.

157. The method of claim 130 or 131, wherein the matrix metalloproteinase has a molecular weight of approximately 150 kDa.

158. The method of claim 130 or 131, wherein the matrix metalloproteinase is detected or monitored electrophoretically.

159. The method of claim 158, wherein the electrophoretic pattern is a zymogram.

U.S. Serial No. 09/469,637

- 18 -

Group Art Unit: 1623

160. The method of claim 130 or 131, wherein the matrix metalloproteinase is detected or monitored immunochemically.

161. The method of claim 160, wherein matrix metalloproteinase is detected or monitored by a radio-immune assay.

162. The method of claim 160, wherein the matrix metalloproteinase is detected or monitored by an enzyme-linked immunosorbant assay.